Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
  • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
  • A61K47/40—Cyclodextrins; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/575—Hormones
  • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present disclosure generally relates to the field of growth hormone (GH) secretagogues, and more specifically to formulations of Growth Hormone-Releasing Hormone (GHRH) analogs such as tesamorelin and methods of administration thereof.
• GH growth hormone
• GHRH Growth Hormone-Releasing Hormone
• Tesamorelin (frans-3-hexenoyl-GHRH (i-44) -NH 2 , FIG. 1) is a stabilized synthetic peptide analogue of the hypothalamic peptide GHRH indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It mediates its effect by acting on the pituitary somatotroph cells to stimulate the synthesis and pulsatile release of endogenous GH, which is both anabolic and lipolytic.
• Tesamorelin exerts its therapeutic effects by binding to, and being an agonist of GHRHr on pituitary somatotrophs; the triggered release GH in turn acts on a variety of target cells, including chondrocytes, osteoblasts, myocytes, hepatocytes and adipocytes, resulting in a host of pharmacodynamic effects, which are primarily mediated by insulin-like growth factor 1 (IGF-1) produced in the liver and in peripheral tissues.
• IGF-1 insulin-like growth factor 1
• the approved daily dosage of tesamorelin for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy is 2 mg administered by subcutaneous injection of 2 ml of a 1 mg/mL tesamorelin solution into abdominal skin. It is currently supplied to patients in two vials each comprising 1 mg of lyophilized tesamorelin.
• the patients must resuspend the lyophilized tesamorelin in the first vial with 2.2 mL of sterile water using a syringe with a first mixing needle, collect the prepared tesamorelin solution from the first vial, change the needle, add the prepared tesamorelin solution to the second vial with the second mixing needle, collect the prepared tesamorelin solution from the second vial, replace the second mixing needle with an injection needle, and subcutaneously inject 2 mL of the prepared tesamorelin solution.
• This relatively complicated process for preparing the injectable tesamorelin solution is not very convenient for patients, and increases the risk of error, contaminations and improper handling of the tesamorelin solution.
• the volume of solution that must be subcutaneously injected to provide the suitable plasmatic tesamorelin levels to the patients is relatively large (2 ml), which may be associated with pain at the injection site (Usach et al., Adv Ther (2019) 36:2986-2996). Further, it would be more convenient for patients to have for example a single vial containing a dosage for treatment, or even a multidose vial containing multiple dosages for treatment (e.g., for multiple days of treatment).
• the present disclosure generally relates to formulations of Growth Hormone-Releasing Hormone (GHRH) analogs, such as tesamorelin, and methods of administration thereof.
• GHRH Growth Hormone-Releasing Hormone
• the present disclosure provides a pharmaceutical composition
• a pharmaceutical composition comprising a GHRH molecule or a pharmaceutically acceptable salt thereof (e.g., frans-3-hexenoyl-GHRH (i- 4) - NH 2 or a pharmaceutically acceptable salt thereof) and at least one pharmaceutically acceptable excipient.
• a GHRH molecule or a pharmaceutically acceptable salt thereof e.g., frans-3-hexenoyl-GHRH (i- 4) - NH 2 or a pharmaceutically acceptable salt thereof
• the present disclosure further provides the following items:
• a pharmaceutical composition comprising (i) about 1.23 to about 1.32 mg of frans-3-hexenoyl- GHRH (i -44 ) -NH 2 or a pharmaceutically acceptable salt thereof at a concentration of about 7.5 mg/mL or more; and (ii) at least one pharmaceutically acceptable excipient.
• composition of item 1 comprising about 1.25 to about 1.30 mg of trans- 3-hexenoyl-GHRH (i-44) -NH 2 or pharmaceutically acceptable salt thereof.
• composition of item 1 or 2 comprising about 1.27 to about 1.29 mg of frans-3-hexenoyl-GHRH (i-44) -NH 2 or pharmaceutically acceptable salt thereof.
• composition of any one of items 1 to 4, wherein the frans-3-hexenoyl- GHRH (i -44 ) -NH 2 or pharmaceutically acceptable salt thereof is at a concentration of about 7.5 to about 8.5 mg/mL.
• composition of any one of items 1 to 11 wherein the at least one pharmaceutically acceptable excipient comprises a surfactant.
• the method of item 25, comprising administering about 1.25 to about 1.30 mg of trans-3- hexenoyl-GHRH (i -44 ) -NH 2 or a pharmaceutically acceptable salt thereof.
• a first container comprising at least about 1.23 to about 1.32 mg of lyophilized trans- 3- hexenoyl-GHRH (i -44 ) -NH 2 or a pharmaceutically acceptable salt thereof;
• a pharmaceutical composition comprising frans-3-hexenoyl-GHRH (i- 4) -NH 2 or a pharmaceutically acceptable salt thereof for use in producing plasmatic levels of trans- 3- hexenoyl-GHRH (i -44 ) -NH 2 or a pharmaceutically acceptable salt thereof in a subject that are bioequivalent to administration of 2 mg of frans-3-hexenoyl-GHRH (i- 4) -NH 2 at a concentration of 1 mg/ml_, wherein the pharmaceutical composition is for administration of about 1.3 to about 1.6 mg or about 1.23 to about 1.32 mg of frans-3-hexenoyl-GHRH (i- 4) -NH 2 or a pharmaceutically acceptable salt thereof at a concentration of about 7.5 mg/ml_ or more, to the subject.
• a pharmaceutical composition comprising frans-3-hexenoyl-GHRH (i- 4) -NH 2 or a pharmaceutically
• the pharmaceutical composition for use of item 34 or 35 wherein the pharmaceutical composition is for administration of about 1.25 to about 1.30 mg of frans-3-hexenoyl-GHRH (i - 44 ) -NH 2 or a pharmaceutically acceptable salt thereof.
• the pharmaceutical composition for use of any one of items 34 to 37, wherein the pharmaceutically acceptable salt of frans-3-hexenoyl-GHRH (i-44) -NH 2 is an acetate salt.
• the pharmaceutical composition for use of any one of items 34 to 39, wherein the trans- 3- hexenoyl-GHRH (i -44 ) -NH 2 or pharmaceutically acceptable salt thereof is for administration by subcutaneous injection.
• a pharmaceutical composition comprising frans-3-hexenoyl-GHRH (i- 4) -NH 2 or a pharmaceutically acceptable salt thereof for producing plasmatic levels of frans-3-hexenoyl- GHRH (i -44 ) -NH 2 or a pharmaceutically acceptable salt thereof in a subject that are bioequivalent to administration of 2 mg of frans-3-hexenoyl-GHRH (i- 4) -NH 2 at a concentration of 1 mg/ml_, wherein the pharmaceutical composition is for administration of about 1.23 to about 1.32 mg of frans-3-hexenoyl-GHRH (i- 4) -NH 2 or a pharmaceutically acceptable salt thereof at a concentration of about 7.5 mg/ml_ or more, to the subject.
• frans-3-hexenoyl-GHRH (i-44) -NH 2 or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for producing plasmatic levels of trans- 3- hexenoyl-GHRH (i -44 ) -NH 2 or a pharmaceutically acceptable salt thereof in a subject that are bioequivalent to administration of 2 mg of frans-3-hexenoyl-GHRH (i- 4) -NH 2 at a concentration of 1 mg/ml_, wherein the pharmaceutical composition is for administration of about 1.23 to about 1.32 mg of frans-3-hexenoyl-GHRH (i- 4) -NH 2 or a pharmaceutically acceptable salt thereof at a concentration of about 7.5 mg/ml_ or more, to the subject. 45.
• Use of frans-3-hexenoyl-GHRH (i-44) -NH 2 or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for administration to a human subject for producing
• any one of items 42 to 49, wherein the frans-3-hexenoyl-GHRH (i- 4) -NH 2 or pharmaceutically acceptable salt thereof is for administration by subcutaneous injection.
• any one of items 42 to 50 further comprising resuspending lyophilized trans- 3- hexenoyl-GHRH (i -44 ) -NH 2 or pharmaceutically acceptable salt thereof in a suitable amount of a pharmaceutically acceptable diluent to obtain a frans-3-hexenoyl-GHRH (i- 4) -NH 2 or trans- 3-hexenoyl-GHRH (i-44) -NH 2 salt solution at a concentration of about 7.5 mg/ml_ or more; thereby to provide the formulation for administration.
• FIG. 1 shows the structure of tesamorelin (frans-3-hexenoyl-GHRH (i- 4) -NH 2 ; SEQ ID NO: 1).
• the term “about” has its ordinary meaning.
• the term “about” is used to indicate that a value includes an inherent variation of error for the device or the method being employed to determine the value, or encompass values close to the recited values, for example within 10% of the recited values (or range of values).
• tesamorelin formulated at 8 mg/mL is more bioavailable that corresponding tesamorelin formulations at 1 mg/mL.
• Pharmacokinetic (PK) studies in human subjects have shown that administration of 1.28 mg of tesamorelin formulated at 8 mg/ml_ is bioequivalent to administration of 2 mg of a 1 mg/ml_ tesamorelin formulation (e.g., the EgriftaTM formulation), the approved daily dosage of tesamorelin (EGRIFTA ® ).
• the present disclosure provides a pharmaceutical composition
• a pharmaceutical composition comprising (i) more than 1.2 mg and less than 1.36 mg, for example about 1.21 to about 1.35, about 1.22 to about 1.33 or 1.34, or about 1.23 to about 1.32 mg of a GHRH molecule or a pharmaceutically acceptable salt thereof, preferably frans-3-hexenoyl-GHRH (i- 4) -NH 2 or a pharmaceutically acceptable salt thereof, at a concentration of about 7.5 mg/ml_ or more; and (ii) at least one pharmaceutically acceptable excipient.
• the pharmaceutical composition comprises from about 1.21 , 1.22, 1.23, 1.24, 1.25, 1.26, or 1.27 mg to about 1.29, 1.30, 1.31, 1.32, 1.33, 1.34 or 1.35 mg of the GHRH molecule, preferably frans-3-hexenoyl-GHRH (i- 4) -NH 2 or a pharmaceutically acceptable salt thereof.
• the pharmaceutical composition comprises from about 1.24 to about 1.31 mg of the GHRH molecule, preferably frans-3-hexenoyl-GHRH (i- 4) -NH 2 or a pharmaceutically acceptable salt thereof.
• the pharmaceutical composition comprises from about 1.25 to about 1.30 mg of the GHRH molecule, preferably trans- 3-hexenoyl-GHRH (i-44) -NH 2 or a pharmaceutically acceptable salt thereof. In a further embodiment, the pharmaceutical composition comprises from about 1.26 to about 1.29 mg of the GHRH molecule, preferably frans-3-hexenoyl-GHRH (i- 4) -NH 2 or a pharmaceutically acceptable salt thereof. In a further embodiment, the pharmaceutical composition comprises from about 1.27 to about 1.29 mg of the GHRH molecule, preferably frans-3-hexenoyl-GHRH (i- 4) -NH 2 or a pharmaceutically acceptable salt thereof. In a further embodiment, the pharmaceutical composition comprises from about 1.28 mg of the GHRH molecule, preferably frans-3-hexenoyl- GHRH (i -44 ) -NH 2 or a pharmaceutically acceptable salt thereof.
• the GHRH molecule preferably frans-3-hexenoyl-GHRH (i- 4) -NH 2 or a pharmaceutically acceptable salt thereof, is at a concentration of about 12, 10 or 8 mg/ml_ or less. In embodiments, the GHRH molecule, preferably frans-3-hexenoyl-GHRH (i- 4) -NH 2 or a pharmaceutically acceptable salt thereof, is at a concentration of about 7.5 to about 10, 9, 8.5 or 8 mg/ml_, for example a concentration of about 7.5 to about 8.5 mg/ml_.
• the GHRH molecule preferably frans-3-hexenoyl-GHRH (i- 4) -NH 2 or a pharmaceutically acceptable salt thereof, is at a concentration of about 7.5, 7.6, 7.7, 7.8 or 7.9 to about 8.1 , 8.2, 8.3, 8.4 or 8.5 mg/ml in the pharmaceutical composition.
• the GHRH molecule preferably frans-3-hexenoyl-GHRH (i- 4) -NH 2 or a pharmaceutically acceptable salt thereof, is at a concentration of about 7.80, 7.82, 7.84, 7.86, 7.88, 7.9, 7.92, 7.94, 7.95, 7.96, 7.97, 7.98 or 7.99 to about 8.01 , 8.02, 8.03, 8.04, 8.05, 8.06, 8.08, 8.1 , 8.12, 8.14, 8.16, 8.18 or 8.2 mg/ml_ in the pharmaceutical composition.
• the GHRH molecule, preferably frans-3-hexenoyl-GHRH (i- 4) -NH 2 or a pharmaceutically acceptable salt thereof is at a concentration of about 8 mg/ml_.
• GHRH molecule includes, without limitation, human native GHRH ( I- 4 ) and fragments thereof (e.g., GHRH ( I- 4O) , GHRH (i-2g) , fragments ranging between 1-29 and the 1-44 sequence), and any other fragments; GHRH from other species and fragments thereof; GHRH variants containing amino acid(s) substitution(s), addition(s) and/or deletion(s); derivatives or analogs of GHRH or fragments or variants thereof having for example an organic group or a moiety coupled to the GHRH amino acid sequence at the N-terminus, the C-terminus or on the side-chain; and pharmaceutically acceptable salts of GHRH (human or from other species), as well as pharmaceutically acceptable salts of GHRH fragments, variants, analogs and derivatives.
• human native GHRH I- 4
• fragments thereof e.g., GHRH ( I- 4O) , GHRH (i-2g) , fragments ranging between 1-29
• the GHRH molecules of the present disclosure also encompass the GHRH molecules currently known in the art, including, without limitation, albumin- conjugated GHRH (U.S. Patent No. 7,268,113); pegylated GHRH peptide (U.S. Patent Nos. 7,256,258 and 6,528,485); porcine GHRH (1-40) (U.S. Patent No. 6,551 ,996); canine GHRH (U.S. patent application no. 2005/0064554); GHRH variants of 1-29 to 1-44 amino acid length (U.S. Patent Nos. 5,846,936, 5,696,089, 5,756,458 and 5,416,073, and U.S. patent application Nos. 2006/0128615 and 2004/0192593); and Pro°-GHRHpeptide and variants thereof (U.S. Patent No. 5,137,872).
• GHRH analogs include those described in U.S. Patent Nos. 5,681 ,379 and 5,939,386, which also describe their method of synthesis. More particularly, these GHRH analogs are defined by the following formula A:
• A1 is Tyr or His
• A2 is Val or Ala
• A8 is Asn or Ser
• A13 is Val or lie
• A15 is Ala or Gly;
• A18 is Ser or Tyr;
• A24 is Gin or His
• A25 is Asp or Glu
• A27 is Met, lie or Nle
• A28 is Ser or Asn
• A30 is absent or is any amino acid, preferably Gin;
• A31 is absent or is any amino acid, preferably Gin;
• A32 is absent or is any amino acid, preferably Gly;
• A33 is absent or is any amino acid, preferably Glu;
• A34 is absent or is any amino acid, preferably Ser;
• A35 is absent or is any amino acid, preferably Asn;
• A36 is absent or is any amino acid, preferably Gin;
• A37 is absent or is any amino acid, preferably Glu;
• A38 is absent or is any amino acid, preferably Arg;
• A39 is absent or is any amino acid, preferably Gly;
• A40 is absent or is any amino acid, preferably Ala;
• A41 is absent or is any amino acid, preferably Arg;
• A42 is absent or is any amino acid, preferably Ala;
• A43 is absent or is any amino acid, preferably Arg;
• A44 is absent or is any amino acid, preferably Leu;
• the group X is a hydrophobic tail anchored via an amide bond to the N-terminus of the peptide and the hydrophobic tail defining a backbone of 5 to 7 atoms.
• the backbone can be substituted by Ci_ 6 alkyl, C 3-6 cycloalkyl, or C 6 -i 2 aryl and the backbone comprises at least one rigidifying moiety connected to at least two atoms of the backbone.
• the rigidifying moiety is a double bond, triple bond, saturated or unsaturated C 3.g cycloalkyl, or C 6 -i 2 aryl.
• group X is: [0031]
• A30-A44 are: (a) absent; (b) an amino acid sequence corresponding to positions 30-44 of a native GHRH peptide (SEQ ID NO: 3), or (c) the amino acid sequence of (b) having a 1-14 amino acid deletion from its C-terminus.
• the GHRH peptide is a polypeptide comprising the amino acid sequence of SEQ ID NO: 4.
• the GHRH molecule is (hexenoyl trans-3)hGHRH (i-44) NH 2 (SEQ ID NO:
• [trans-3-hexenoyl]hGHRH (i- 4) amide (also referred to as (hexenoyl trans-3)hGHRH(1-44)NH 2 ) is a synthetic human GHRH (hGHRH) analog that comprises the 44-amino acid sequence of hGHRH on which a hexenoyl moiety, a C 6 side chain, has been anchored on the amino-terminal tyrosine residue.
• the structure of [trans-3- hexenoyl]hGHRH (i -44) amide is depicted at FIG. 1.
• salts of GHRH molecules that are pharmacologically acceptable and substantially non-toxic to the subject to which they are administered. More specifically, these salts retain the biological effectiveness and properties of the GHRH molecule and are formed from suitable non-toxic organic or inorganic acids or bases.
• these salts include acid addition salts of GHRH molecules which are sufficiently basic to form such salts.
• Such acid addition salts include acetates, adipates, alginates, lower alkanesulfonates such as a methanesulfonates, trifluoromethanesulfonates or ethanesulfonates, arylsulfonates such as a benzenesulfonates, 2-naphthalenesulfonates, or toluenesulfonates (also known as tosylates), ascorbates, aspartates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, cinnamates, cyclopentanepropionates, digluconates, dodecylsulfates, ethanesulfonates, fumarates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, he
• salts can be formed quite readily by those skilled in the art using standard techniques. Indeed, the chemical modification of a pharmaceutical compound (i.e. drug) into a salt is a technique well known to pharmaceutical chemists, (See, e.g., H. Ansel et. al., Pharmaceutical Dosage Forms and Drug Delivery Systems (6 th Ed. 1995) at pp. 196 and 1456- 1457). Salts of the GHRH molecules may be formed, for example, by reacting the GHRH molecule with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
• an amount of acid or base such as an equivalent amount
• the pharmaceutically acceptable salt of the GHRH molecule preferably [trans-3-hexenoyl]hGHRH (i-44) amide, is an acetate salt.
• pharmaceutically acceptable excipient has its normal meaning in the art and is any ingredient that is not an active ingredient (drug) itself. Excipients include for example binders, lubricants, diluents, bulking agents (fillers), thickening agents, disintegrants, plasticizers, coatings, barrier layer formulations, lubricants, stabilizing agent, release-delaying agents and other components. "Pharmaceutically acceptable excipient” as used herein refers to any excipient that does not interfere with effectiveness of the biological activity of the active ingredients and that is not toxic to the subject, i.e., is a type of excipient and/or is for use in an amount which is not toxic to the subject.
• the pharmaceutical composition comprises one or more excipients, including for example and without limitation, one or more binders (binding agents), thickening agents, surfactants, diluents, release-delaying agents, colorants, flavoring agents, fillers, disintegrants/dissolution promoting agents, lubricants, plasticizers, silica flow conditioners, glidants, anti-caking agents, anti-tacking agents, stabilizing agents, anti-static agents, swelling agents and any combinations thereof.
• binders binding agents
• thickening agents surfactants
• diluents release-delaying agents
• colorants colorants
• flavoring agents fillers
• disintegrants/dissolution promoting agents lubricants
• plasticizers plasticizers
• silica flow conditioners silica flow conditioners
• glidants anti-caking agents
• anti-tacking agents stabilizing agents
• anti-static agents swelling agents and any combinations thereof.
• a single excipient can fulfill more than two functions at once, e.g., can act as both a binding agent and a thickening agent. As those of skill will also recognize, these terms are not necessarily mutually exclusive.
• Therapeutic formulations are prepared using standard methods known in the art by mixing the active ingredient having the desired degree of purity with one or more optional pharmaceutically acceptable carriers, excipients and/or stabilizers.
• the excipient(s) may be suitable, for example, for intravenous, parenteral, subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intracapsular, intraspinal, intrathecal, epidural, intracisternal, intraperitoneal, intranasal or pulmonary (e.g., aerosol) administration (see Remington: The Science and Practice of Pharmacy, by Loyd V Allen, Jr, 2012, 22 nd edition, Pharmaceutical Press; Handbook of Pharmaceutical Excipients, by Rowe etal., 2012, 7 th edition, Pharmaceutical Press).
• the pharmaceutical composition is an injectable composition, such as an injectable solution or suspension.
• the pharmaceutical composition comprises one or more excipients for subcutaneous administration/injection.
• the pharmaceutical composition comprises a bulking agent.
• the term "bulking agent” as used herein refers to a compound used to provide an adequate or desired tonicity of the solution resulting from the reconstitution of the lyophilized formulation.
• the adequate or desired tonicity of the solution is equal to or approximates isotonicity with physiological fluid of the subject to which the solution is administered.
• one or more sugars may be used as the bulking agent.
• Sugars, as used herein, include, but are not limited to, monosaccharides, oligosaccharides and polysaccharides.
• the bulking agent is mannitol.
• one or more amino acids such as glycine, may be used as the bulking agent.
• the bulking agent is in concentration of about 1% to about 10% (w/w) or about 2% to about 8% (w/w) in the pharmaceutical composition.
• the bulking agent is in concentration of about 3 to about 5% (w/w) in the pharmaceutical composition.
• the bulking agent is in concentration of about 4% (w/w) in the pharmaceutical composition.
• the pharmaceutical composition of the present disclosure may further comprise a surfactant.
• surfactants include sorbitan fatty acid esters such as sorbitan monocaprylate, sorbitan monolaurate, sorbitan monopalmitate; glycerin fatty acid esters such as glycerin monocaprylate, glycerin monomyristate, glycerin monostearate; polyglycerin fatty acid esters such as decaglyceryl monostearate, decaglyceryl distearate, decaglyceryl monolinoleate; polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan monopalmitate, polyoxyethylene sorbitan trioleate, polyoxyethylene sorbitan tristearate; polyoxyethylene sorbitol fatty acid esters such as sorbitan monocap
• the surfactant the pharmaceutical composition of the present disclosure is a non-ionic surfactant.
• the surfactant the pharmaceutical composition of the present disclosure is a polyoxyethylene sorbitan alkyl ester, e.g. polysorbate.
• the surfactant the pharmaceutical composition of the present disclosure is polysorbate-20 (T20 or Tween-20TM).
• the amount of surfactant in the pharmaceutical composition of the present disclosure is about 0.0001% to about 10% (w/w). In a further embodiment, the amount of surfactant in the pharmaceutical composition of the present disclosure is about 0.001% to about 5%, 1% or 0.1% (w/w) or about 0.005% to about 0.05%. In yet a further embodiment, the amount of surfactant in the pharmaceutical composition of the present disclosure is about 0.01% (w/w).
• the pharmaceutical composition of the present disclosure may further comprise one or more stabilizing agents or stabilizers.
• stabilizer is intended to mean a compound used to stabilize the therapeutic agent against physical, chemical, or biochemical process that would reduce the therapeutic activity of the agent.
• Suitable stabilizers are non-reducing sugars including, by way of example and without limitation, sucrose (or saccharose) and trehalose; and non-reducing polyols or sugar alcohols including, by way of example and without limitation, sorbitol, mannitol, maltitol, xylitol, glycol, glycerol and ethylene glycol.
• the amount of stabilizing agent in the pharmaceutical composition of the present disclosure is about 0.05% to about 10% (w/w).
• the amount of stabilizing agent in the pharmaceutical composition of the present disclosure is about 1% to about 5%, about 2% to about 4% or about 2.5% to about 3.5% (w/w).
• the amount of surfactant in the pharmaceutical composition of the present disclosure is about 3% (w/w).
• the pharmaceutical composition of the present disclosure comprises a non-reducing sugar.
• “Non-reducing sugar” as used herein refers to a sugar that does not contain a hemi-acetal, for example a carbohydrate or sugar characterized by having a glycosidic bond formed between the reducing ends of the sugar units, and not between a reducing end of one sugar unit and a non-reducing end of the other sugar unit.
• the above- mentioned non-reducing sugar is trehalose or sucrose.
• the above- mentioned non-reducing sugar is sucrose.
• the non-reducing sugar is in a concentration of about 0.1% to about 5% (w/w) in the pharmaceutical composition of the disclosure.
• the non-reducing sugar is in a concentration of about 1% to about 3% (w/w).
• the non-reducing sugar is in a concentration of about 2% (w/w).
• the pharmaceutical composition of the present disclosure comprises a buffering agent, i.e. an agent that maintains the pH of the pharmaceutical composition near a chosen value.
• buffering agents include acetate buffers, succinate buffers, citrate buffers, phosphate buffers and histidine buffers.
• the buffering agent is a histidine buffer.
• the concentration of histidine in the pharmaceutical composition is about 0.01% to about 1%, for example about 0.05% to about 0.5% or about 0.1% to about 0.3%.
• the histidine sugar is in a concentration of about 0.15%.
• the pharmaceutical composition of the present disclosure comprises an oligosaccharide, for example a cyclic oligosaccharide such as a cyclodextrin.
• a cyclic oligosaccharide such as a cyclodextrin.
• cyclodextrin refers to a family of cyclic oligosaccharides, comprising a macrocyclic ring of glucopyranoside subunits (5 or more) joined by a-1 ,4 glycosidic bonds.
• cyclodextrins examples include a-cyclodextrin, b-cyclodextrin and y-cyclodextrin, which comprise 6, 7 and 8 glucopyranoside subunits, respectively, as well as analogs thereof (e.g., modified cyclodextrins).
• the cyclodextrin is a b-cyclodextrin or a modified b-cyclodextrin.
• b-cyclodextrin has the following structure: [0049] One or more of the hydroxyl groups of one or more of the sugar units may be modified, for example with an alkyl, alkenyl or alkynyl group, or with a substituted alkyl, alkenyl or alkynyl group. Therefore, in embodiments, the b-cyclodextrin may be unmodified or unsubstituted, or may be modified or substituted. As such, in a further embodiment, the b-cyclodextrin is a modified b- cyclodextrin.
• Modified b-cyclodextrin refers to a b-cyclodextrin that contains a modification at one or more hydroxyl groups of one or more sugar units of the b-cyclodextrin, i.e., a group or moiety that is attached to one or more hydroxyl groups of one or more sugar units of the b-cyclodextrin.
• the modified b-cyclodextrin is an alkyl-, alkenyl-, alkynyl, substituted alkyl-, substituted alkenyl or substituted alkynyl ⁇ -cyclodextrin (e.g., with a hydroxyl substitution).
• the alkyl, alkenyl or alkynyl groups are (Ci-C 6 )alkyl, (Cr C 6 )alkenyl or (Ci-C 6 )alkynyl groups.
• the modified b-cyclodextrin is a (Cr C 6 )alkyl b-cyclodextrin, in a further embodiment methyl ⁇ -cyclodextrin (M-b-CD).
• the modified b-cyclodextrin is a hydroxy(Ci-C 6 )alkyl b-cyclodextrin, in a further embodiment hydroxypropyl ⁇ -cyclodextrin (HR-b-CD).
• the cyclodextrin is present in the pharmaceutical composition at a concentration of about 2 to about 15 % (w/v), in a further embodiment about 2 to about 12.5 % (w/v), for example about 2 to about 10 % (w/v), about 2.5 to about 15 % (w/v), about 2.5 to about 12.5 % (w/v), about 2.5 to about 10 % (w/v), about 5 to about 15 % (w/v), about 5 to about 12.5 % (w/v), about 5 to about 10 % (w/v), about 7.5 to about 12.5 % (w/v), about 7.5 to about 10 %
• the pharmaceutical composition of the present disclosure has a pH of about 4.5 to about 6.5, for example about 5.0 to about 6.0. According to another embodiment, the pharmaceutical composition has a pH of about 5.0. According to a further embodiment, the pharmaceutical composition has a pH of about 5.5. According to another further embodiment, the pharmaceutical composition has a pH of about 5.9-6.0.
• the pharmaceutical composition of the present disclosure comprises a diluent, for example an aqueous solution.
• the pharmaceutical composition comprises (typically sterile) water.
• the pharmaceutical composition of the present disclosure may further contain other diluents, solubilizing agents, excipients, pH-modifiers, soothing agents, buffers, sulfur-containing reducing agents, antioxidants or the like, if desired.
• sulfur-containing reducing agents include N-acetylcysteine, N-acetylhomocysteine, thioctic acid, thiodiglycol, thioethanolamine, thioglycerol, thiosorbitol, thioglycolic acid and salts thereof, sodium thiosulfate, glutathione, methionine and sulfhydryl-containing compounds such as thioalkanoic acid having 1 to 7 carbon atoms.
• Antioxidants include methionine, erythorbic acid, dibutylhydroxytoluene, butylhydroxyanisole, a-tocopherol, tocopherol acetate, L-ascorbic acid and salts thereof, L- ascorbyl palmitate, L-ascorbyl stearate, sodium bisulfite, sodium sulfite, triamyl gallate, propyl gallate or chelating agents such as disodium ethylenediamine tetraacetate (EDTA), sodium pyrophosphate, sodium metaphosphate.
• EDTA disodium ethylenediamine tetraacetate
• inorganic salts such as sodium chloride, potassium chloride, calcium chloride, sodium phosphate, potassium phosphate, sodium bicarbonate; and organic salts such as sodium citrate, potassium citrate, sodium acetate.
• the pharmaceutical composition is stable at room temperature.
• a stable composition is a composition in which the active principal ingredient, i.e. the GHRH molecule (e.g., [trans-3-hexenoyl]hGHRH (1-44) amide) therein essentially retains its physical and chemical stability and integrity upon storage.
• GHRH molecule e.g., [trans-3-hexenoyl]hGHRH (1-44) amide
• Stability can be measured at a selected temperature for a selected time period.
• the composition may be kept, for example, at 40°C for 2 weeks to 1 month (and for up to 6 months), at which time stability is measured.
• the composition may also be kept, for example, at in ambient room temperature conditions (about 15-30°C, preferably about 20-25°C) for at least 6 months, at which time stability is measured.
• the composition of the present disclosure preserves the stability of the GHRH molecule (e.g., [trans- 3-hexenoyl]hGHRH (1-44) amide) in lyophilized form for a period of storage at room temperature (i.e.
• a “stable" composition may be one wherein more than about 80%, more than about 90%, more than about 95%, more than about 96%, more than about 97%, more than about 98%, or more than about 99% of the non-degraded active agent is present in the composition upon the storage period.
• the stability of the composition of the present disclosure may for example be measured using reverse phase high pressure liquid chromatography (RP-HPLC).
• the pharmaceutical composition has a pH of about 5.8 to about 6.2 and comprises:
• GHRH molecule e.g., [trans-3-hexenoyl]hGHRH (1- 44) amide
• a cyclodextrin for example a b-cyclodextrin such as hydroxypropyl-p-cyclodextrin (HR-b-CD)
• the pharmaceutical composition has a pH of about 5.9 to about 6.1 and comprises:
• GHRH molecule e.g., [trans-3- hexenoyl]hGHRH (1-44) amide
• a cyclodextrin for example a b-cyclodextrin such as hydroxypropyl ⁇ -cyclodextrin (HR-b-CD)
• composition of the present disclosure may be useful for inducing or increasing GH secretion in a subject.
• the present disclosure provides a method for inducing or increasing GH secretion in a subject in need thereof, said method comprising administering to said subject an effective amount of the above-mentioned formulation or composition.
• the present disclosure provides a use of the above-mentioned formulation or composition, for inducing or increasing growth hormone secretion in a subject.
• the present disclosure provides a use of the above-mentioned formulation or composition, for the preparation of a medicament for inducing or increasing GH secretion in a subject.
• the terms “stimulating,” “increasing,” or “inducing” or any variations of these terms as used herein, refer to a measurable increase of a biological activity.
• the increase is at least a 10%, 20%, 40%, 60%, 80%, 90%, 95%, 100% (2-fold), 200% (3-fold) increase in the biological activity relative to a control.
• a GRF analog is found to stimulate GHRHr activity when an increase in GH levels is measured following administration of the GHRH molecule to a subject (e.g., animal, human) in comparison to a subject not administered with the GHRH molecule.
• compositions of the disclosure may be useful as a medicament, for prophylactic and/or therapeutic applications in which stimulation of GH secretion is desirable, for example for the treatment or prevention of conditions/disorders/diseases associated with GHRH and/or GH function (e.g., in which reduced GH and/or GHRH function is involved in the etiology of the disease/disorder).
• Such conditions/disorders/diseases include, for example, syndromes associated with fat accumulation, hypercholesterolemia, obesity, syndrome X, lipohypertrophy, lipoatrophy, lipodystrophy (e.g., HIV-associated lipodystrophy syndrome), impaired cognitive function, impaired daytime vigilance, declined function of the immune system (e.g., immunodeficiencies such as T-cell deficiencies), muscle protein catabolism, diseases/conditions associated with muscle wasting such as sarcopenia, frailty, radiotherapy- and/or chemotherapy-related side effects (e.g., in HIV-infected and cancer patients), cachexia (e.g., in cancer patients), hypothalamic pituitary dwarfism, burns, osteoporosis, renal failure, nonunion bone fracture, acute/chronic debilitating illness or infection, wound healing, post-surgical problems, lactation failure, infertility in women, neurodegenerative conditions, GRF receptor- dependent tumors, conditions related to aging, sleep disorders
• the subject to whom the composition or formulation is administered suffers from one or more of the diseases or conditions described herein.
• the subject suffers from lipodystrophy (e.g., HIV-associated lipodystrophy syndrome).
• the subject suffers from NAFLD or NASH.
• the present disclosure provides a method for (1) stimulating daytime vigilance and/or cognitive function, e.g. in conditions related to aging, mild cognitive impairment (MCI), pre-Alzheimer’s symptoms (Pre-Onset Alzheimer's), dementia and/or sleep impairment (e.g., age-related sleep impairment), (2) improving/preventing/treating metabolic conditions associated with fat accumulation and/or hypercholesterolemia (obesity, abdominal obesity/adiposity, abdominal obesity with metabolic disorders, abdominal obesity with relative GH deficiency, metabolic syndrome or syndrome X, lipohypertrophy, lipoatrophy, lipodystrophy (e.g., HIV-associated lipodystrophy syndrome), dyslipidemia, hypertriglyceridemia), NAFLD/NASH (3) improving anabolism in catabolic/wasting conditions, such as those observed in acute or chronic renal failure (e.g., acute or chronic renal failure wasting), chronic heart failure (e.g., chronic heart failure wasting), chronic ob
• MCI mild cognitive impairment
• the present disclosure provides a use of the above-mentioned composition for achieving one or more of the biological/therapeutic effects (1) to (14) noted above, e.g. for improving, preventing and/or treating the conditions, diseases or disorders noted above, or for the preparation/manufacture of a medicament for improving, preventing and/or treating the conditions, diseases or disorders noted above.
• the present disclosure provides the above-mentioned composition for use in improving, preventing and/or treating the conditions, diseases or disorders noted above, or for the preparation/manufacture of a medicament for improving, preventing and/or treating the conditions, diseases or disorders noted above.
• treatment is defined as the application or administration of a therapeutic agent to a subject, or application or administration of a therapeutic agent to an isolated tissue or cell line from a subject, who has a disorder, a disease, a symptom of disorder or disease, or a predisposition toward a disorder or disease, with the purpose to cure, heal, alleviate, delay, relieve, alter, remedy, ameliorate, improve or affect the disorder/disease, the symptoms of disorder/disease or the predisposition toward disorder/disease.
• the present disclosure provides a method of administering a GHRH molecule to a subject, preferably frans-3-hexenoyl-GHRH (i- 4) -NH 2 , to a subject to obtain plasmatic levels of the GHRH molecule that are bioequivalent to administration of 2 mg of the GHRH molecule at a concentration of 1 mg/ml_ (e.g., the EGRIFTATM formulation comprising 5% mannitol), the method comprising administering to the subject more than 1.2 mg and less than 1.36 mg, for example about 1.21 to about 1.35, about 1.22 to about 1.33 or 1.34, or about 1.23 to about 1.32 mg of the GHRH molecule at a concentration of about 7.5 mg/ml_ or more.
• a GHRH molecule preferably frans-3-hexenoyl-GHRH (i- 4) -NH 2
• a subject preferably frans-3-hexenoyl-GHRH (i- 4)
• the GHRH molecule preferably frans-3-hexenoyl-GHRH (i- 4) -NH 2
• the subject suffers from one or more of the conditions, diseases or disorders noted above.
• the subject suffers from HIV-associated lipodystrophy.
• the subject suffers from NAFLD or NASH.
• bioequivalent means that one or more pharmacokinetic (PK) parameters following administration of the GHRH molecule to subjects do not significantly differ between the two treatment regimens, as determined using a suitable statistical standard.
• PK pharmacokinetic
• at least two PK parameters do not significantly differ between the two treatment regimens.
• at least three PK parameters do not significantly differ between the two treatment regimens.
• the one or more PK parameters comprise the maximum plasmatic concentration (C ma x).
• the one or more PK parameters comprise the area under the plasma concentration time curve extrapolated to infinity (AUC 0 - ).
• the one or more PK parameters comprise the cumulative area under the plasma concentration time curve calculated from 0 to T LQ C (time of last observed quantifiable plasma concentration) using the linear trapezoidal method (AUCO-T).
• bioequivalent means that the 90% Cl of the relative mean C ma x, AUC ( o_ t) and AUC ( o_ ) is within 80% to 125% of the reference (EGRIFTA ® ) in the fasting state.
• the natural logarithmic (In) transformation of the one or more PK parameters is used for the statistical analysis.
• the statistical standard used is the ratio of geometric LSmeans with corresponding 90% confidence interval (Cl) for the exponential of the difference between the two treatment regimens for the Least-squares means (LSmeans) of the In-transformed PK parameter(s) that is within the 80.00% to 125.00% range, as described in the Examples below.
• the method permits to achieve a maximum plasmatic concentration (Cm a x) of the GHRH molecule of about 1500 to about 4500 pg/mL in a human subject. In another embodiment, the method permits to achieve an average C ma x of the GHRH molecule of about 2500 to about 3500 pg/mL in a population of human subjects. In further embodiments, the method permits to achieve an average maximum plasmatic concentration C ma x of the GHRH molecule of about 2600 or 2700 to about 3000, 3100 or 3200 pg/mL in a population of human subjects.
• the method permits to achieve an area under the plasma concentration time curve extrapolated to infinity (AUC 0 - ) of the GHRH molecule of about 300 to about 1400 pg-h/mL in a subject. In an embodiment, the method permits to achieve an average AUC 0 - of the GHRH molecule of about 500 to about 1000 pg-h/mL in a population of human subjects. In further embodiments, the method permits to achieve an average AUC 0 - of the GHRH molecule of about 600, 650 or 700 to about 750, 800, 850 or 900 pg/mL in a population of human subjects.
• the method comprises: (a) resuspending a lyophilized GHRH molecule, preferably frans-3-hexenoyl-GHRH (i-44) -NH 2 or a pharmaceutically acceptable salt thereof, in a suitable volume of a pharmaceutically acceptable diluent to obtain a GHRH molecule solution at about 7.5 mg/ml_ or more; and (b) administering a suitable volume of the GHRH solution so that more than 1.2 mg and less than 1.36 mg, for example about 1.21 to about 1.35, about 1.22 to about 1.33 or 1.34, or about 1.23 to about 1.32 mg of the GHRH molecule, preferably frans-3-hexenoyl-GHRH (i-44) -NH 2 or a pharmaceutically acceptable salt thereof, is administered to the subject.
• the method comprises: (a) resuspending a lyophilized GHRH molecule, preferably frans-3-hexenoyl-GHRH (i- 4) -NH 2 or a pharmaceutically acceptable salt thereof, in a suitable volume of a pharmaceutically acceptable diluent to obtain a GHRH molecule solution at about 7.5 to about 8.5 mg/ml_; and (b) administering about 0.144 to about 0.176 mL of the GHRH molecule solution of (a) to the subject, thereby administering about 1.23 to about 1.32 mg of the GHRH molecule.
• the method comprises: (a) resuspending a lyophilized GHRH molecule, preferably frans-3-hexenoyl-GHRH (i- 4) -NH 2 or a pharmaceutically acceptable salt thereof, in a suitable volume of a pharmaceutically acceptable diluent to obtain a GHRH molecule solution at about 7.8 to about 8.2 mg/ml_; and (b) administering about 0.150 to about 0.170 mL of the GHRH molecule solution of (a) to the subject, thereby administering about 1.23 to about 1.32 mg of the GHRH molecule.
• the method comprises: (a) resuspending lyophilized GHRH molecule, preferably frans-3-hexenoyl-GHRH (i- 4) -NH 2 or a pharmaceutically acceptable salt thereof, in a suitable volume of a pharmaceutically acceptable diluent to obtain a GHRH molecule solution at about 8 mg/mL; and (b) administering about 0.16 mL of the GHRH molecule solution of (a) to the subject, thereby administering about 1.28 mg of the GHRH molecule.
• the method comprises: (a) resuspending about 12.5 mg of lyophilized GHRH molecule, preferably frans-3-hexenoyl-GHRH (i- 4) -NH 2 or a pharmaceutically acceptable salt thereof, in about 1.4 mL of a pharmaceutically acceptable diluent to obtain a GHRH molecule solution at about 8 mg/mL; and (b) administering about 0.16 mL of the GHRH molecule solution of (a) to the subject, thereby administering about 1.28 mg of the GHRH molecule.
• the lyophilized GHRH molecule preferably frans-3-hexenoyl-GHRH (i - 44 ) -NH 2 or a pharmaceutically acceptable salt thereof, is in a container, preferably a sealed container, such as a vial.
• the lyophilized GHRH molecule is resuspended using a syringe.
• the GHRH molecule solution is administered by injection, e.g., subcutaneous injection.
• the term "subject” or "patient” are taken to mean a warm-blooded animal such as a mammal, for example, a cat, a dog, a mouse, a guinea pig, a horse, a bovine cow, a sheep or a human.
• a mammal for example, a cat, a dog, a mouse, a guinea pig, a horse, a bovine cow, a sheep or a human.
• the subject is a mammal.
• the above-mentioned subject is a human.
• the present disclosure also provides a kit comprising: (a) a first container comprising at least about 1.21 mg, for example at least about 1.23 to about 1.32 mg of lyophilized GHRH molecule, preferably frans-3-hexenoyl-GHRH (i- 4) -NH 2 or a pharmaceutically acceptable salt thereof; (b) a second container comprising a pharmaceutically acceptable diluent; and (c) instructions for resuspending the lyophilized GHRH molecule, preferably trans- 3- hexenoyl-GHRH (i -44 ) -NH 2 or a pharmaceutically acceptable salt thereof, in the pharmaceutically acceptable diluent to obtain a GHRH molecule solution at about 7.5 mg/ml_ or more.
• the kit comprises: (a) a first container comprising at least about 1.21 mg, for example at least about 1.23 to about 1.32 mg of lyophilized GHRH molecule, preferably frans-3-hexenoyl-GHRH (i-44) -NH 2 or a pharmaceutically acceptable salt thereof; (b) a second container comprising at least 0.16 mL of a pharmaceutically acceptable diluent; and (c) instructions for resuspending the lyophilized GHRH molecule, preferably frans-3-hexenoyl- GHRH (i -44 ) -NH 2 or a pharmaceutically acceptable salt thereof, in the pharmaceutically acceptable diluent to obtain a GHRH molecule solution at about 7.8 to about 8.2 mg/ml_.
• the first container comprises about 12.5 mg of lyophilized trans- 3- hexenoyl-GHRH (i -44 ) -NH 2 or a pharmaceutically acceptable salt thereof.
• the second container comprises about 1.4 mL of the pharmaceutically acceptable diluent.
• the pharmaceutically acceptable diluent is an aqueous solution, for example sterile water.
• the lyophilized GHRH molecule preferably frans-3-hexenoyl-GHRH (i - 44 ) -NH 2 or a pharmaceutically acceptable salt thereof, is in a sealed container, such as a vial.
• the kit further comprises at least one syringe.
• the kit further comprises instructions for administering more than 1.2 mg and less than 1.36 mg, for example about 1.21 to about 1.35, about 1.22 to about 1.33 or 1.34, or about 1.23 to about 1.32 mg of the GHRH molecule to the subject, e.g., by subcutaneous injection.
• Example 1 Bioequivalence study in humans with 1.2 mg, 1.36 mg and 1.6 mg of an 8 mq/ml tesamorelin formulation
• IPs investigational products
• Test product Tesamorelin 12.5 mg/vial sterile lyophilized powder for SC injection, resuspended at 8 mg/ml in a solution comprising 10% hydroxypropyl-p-cyclodextrin (HR-b-CD) and 3% Mannitol (pH 5.9-6).
• EGRIFTA ® tesamorelin 1 mg/vial sterile lyophilized powder for SC injection resuspended at 1 mg/ml in a solution comprising 5% Mannitol.
• Treatment-A A single 1.2 mg (0.15 mL) SC dose of the Test Product
• Treatment-B A single 1.36 mg (0.17 mL) SC dose of the Test Product
• Treatment-C A single 1.6 mg (0.20 mL) SC dose of the Test Product
• Treatment-D A single 2 mg (2.00 mL) SC dose of the Reference Product [0093]
• the treatments were administered according to Table 1 :
• Light-, non- or ex-smoker A light smoker was defined as someone using 10.0 nicotine units or less per day for at least 90 days prior to the first study drug administration.
• An ex-smoker was defined as someone who completely stopped using nicotine products for at least 180 days prior to the first study drug administration.
• Tesamorelin plasma levels were assessed using a validated ELISA assay.
• the lower limit of quantitation (LOQ) and upper limit of quantitation were 150 pg/mL and 6000 pg/mL, respectively.
• T max Time of maximum observed plasma concentration; if it occurs at more than one time point, T max is defined as the first time point with this value
• AUCO-T/INF Relative percentage of AUCO-T with respect to AUCO-INF
• l z and T haif Terminal elimination half-life, calculated as Ih(2)/l z ) were also determined.
• the main absorption and disposition parameters were estimated using a non-compartmental approach with a log-linear terminal phase assumption.
• the trapezoidal rule was used to estimate the AUC (linear trapezoidal linear interpolation) and the terminal phase was estimated by maximizing the coefficient of determination estimated from the log-linear regression model.
• disposition parameters were not estimated for individual concentration-time profiles where the terminal log-linear phase could be reliably characterized using the following criteria:
• Bioequivalence demonstration was based on the 8 mg/ml_ to 1 mg/ml_ ratio of geometric Least-Square means (LSmeans) with corresponding 90% Cl for C max , AUC O -T and AUC O -I N F being within the 80% to 125% acceptance range.
• the 90% confidence interval (Cl) for the exponential of the difference in LSmeans between the Test and Reference products was calculated for the In-transformed parameters (Treatment-A, -B or -C to Treatment-D ratio of geometric LSmeans).
• Safety was assessed by qualified study staff by evaluating the following: reported adverse events (AEs), clinical laboratory test results, vital signs measurements, ECG findings, physical examination findings, visual skin evaluation and glycemia.
• the C ma x , AUC O -T , and AUC 0 - values observed for the 1.2 mg Test Product were 2889.6 pg/mL, 807.6 pg h/mL, and 879.2 pg-h/mL respectively, relative to 3097.7 pg/mL, 949.3 pg h/mL, and 1057.2 pg-h/mL for the 2 mg Reference Product, respectively.
• the geometric least squares mean ratio point estimate were 92.68%, 84.44% and 83.93% for C m ax, AUC O -T and AUC 0 - , respectively.
• the C max , AUC O -T, and AUC 0. « values observed for the 1.36 mg Test Product were 3462.6 pg/mL, 957.1 pg-h/mL and 1029.8 pg-h/mL, respectively, relative to 3097.7 pg/mL, 949.3 pg-h/mL and 1057.2 pg-h/mL for the 2 mg Reference Product, respectively.
• the geometric least squares mean ratio point estimates were 112.77%, 110.32% and 108.31% for C max , AUC 0-T and AUC 0. « , respectively.
• the C ma x, AUC O -T, and AUC 0 - values observed for the 1.6 mg Test Product were 3918.1 pg/mL, 1126.6 pg-h/mL and 1260.1 pg-h/mL, respectively, relative to 3097.7 pg/mL, 949.3 pg-h/mL and 1057.2 pg-h/mL for the 2 mg Reference Product, respectively.
• the geometric least squares mean ratio point estimates were 131.65%, 125.05% and 122.04% for C ma x, AUC O -T and AUC 0. « , respectively.
• the primary objective of this study was to evaluate the pharmacokinetic (PK) of 2 tesamorelin formulations (1 mg/vial and 12.5 mg/vial) after a single subcutaneous (SC) dose administration in healthy subjects.
• PK pharmacokinetic
• Test Tesamorelin for injection, sterile lyophilized powder, 12.5 mg/vial (8 mg/ml_ after resuspension in a solution comprising 10% hydroxypropyl-p-cyclodextrin (HR-b-CD) and 3% Mannitol (pH 5.9-6)).
• In-transformed parameter AUCo-t was to fall within the 80.0 to 125.0% bioequivalence range.
• TPD additional requirements No outliers were found. Moreover, the measured drug content of the lots of the reference and test products did not differ by more than 5% from each other (percent of the label claim), thus the potency-corrected content was not used for the ratios and confidence intervals. [00126] A dose of tesamorelin 1.28 mg (0.16 mL) of a 8 mg/ml_ formulation is judged to be bioequivalent to a dose of 2 mg (2 mL) of the 1 mg/mL formulation and was found to be safe and well tolerated in the subjects.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Endocrinology (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Diabetes (AREA)
• Zoology (AREA)
• Gastroenterology & Hepatology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Obesity (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Hematology (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Inorganic Chemistry (AREA)
• Immunology (AREA)
• Biophysics (AREA)
• Toxicology (AREA)
• Child & Adolescent Psychology (AREA)
• Genetics & Genomics (AREA)
• Dermatology (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Peptides Or Proteins (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (1)

Family

ID=79553399

Family Applications (1)

Country Status (9)

Citations (6)

Family Cites Families (3)

• 2021
  • 2021-06-30 CN CN202180047566.8A patent/CN115884783A/zh active Pending
  • 2021-06-30 IL IL298991A patent/IL298991A/en unknown
  • 2021-06-30 CA CA3183299A patent/CA3183299A1/en active Pending
  • 2021-06-30 KR KR1020237003921A patent/KR20230035600A/ko active Pending
  • 2021-06-30 WO PCT/CA2021/050904 patent/WO2022006657A1/en not_active Ceased
  • 2021-06-30 AU AU2021306736A patent/AU2021306736A1/en active Pending
  • 2021-06-30 US US18/012,496 patent/US20230270865A1/en active Pending
  • 2021-06-30 JP JP2022580982A patent/JP2023533498A/ja active Pending
  • 2021-06-30 EP EP21837118.5A patent/EP4175661A4/en active Pending

Patent Citations (6)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events